HDG, your entire analysis is quantitatively objective. I don't see a pathway for Generics within the context of a competent courtroom, to tease out anything remotely arguable, from any of those you've listed and defined based in law. If I'm not mistaken, Singer won a case in 2017, where he promoted taking an "entirety" approach and not a "cherry picked" approach to evaluating obviousness.
As far as I'm concerned, the stars are aligned. BO negotiations must be ongoing. BPs expect there will always be infringement and patent challenges. This won't be the first, second, or last.
** Amarin's litigation experience has been a boon for BPs. BP's could not "buy" a richer source of information to use, in order to evaluate the strength/weaknesses of Amarin's patents.
I expect feverish BO rumors, talks.. etc happening in Q3, either an announcent of the BO in Q3 or latest Q4. So BP can hit the ground running in 1/2021.
ILT